M S Abdel-Hamid1, M Y Issa2, G A Otaify2, S F Abdel-Ghafar1, H M Elbendary3, M S Zaki2. 1. Medical Molecular Genetics Department, Human Genetics and Genome Research Division, National Research Centre, Cairo, Egypt. 2. Clinical Genetics Department, Human Genetics and Genome Research Division, National Research Centre, Cairo, Egypt. 3. Child Health Department, Medical Research Division, National Research Centre, Cairo, Egypt.
Abstract
BACKGROUND: Hyperphosphatasia with mental retardation syndrome (HPMRS) is caused by recessive mutations in genes involved in the glycosylphosphatidylinsitol pathway, including PGAP3. MATERIALS AND METHODS: We describe 10 patients from 8 Egyptian families presenting with developmental delay, severe intellectual disability, distinct facial dysmorphism and increased alkaline phosphatase. Sanger sequencing of PGAP3 was performed. RESULTS: Eight patients had cleft palate, 4 had postnatal microcephaly and 5 had seizures. Neuro-imaging findings showed thin corpus callosum in 9 patients, mild ventriculomegaly in 3 patients and variable degrees of cerebellar vermis hypoplasia in 4 patients, a finding not previously reported in patients with HPMRS. Additional manifestations included double row teeth, hypogenitalism and congenital heart disease. Biallelic loss of function mutations in the PGAP3 gene were detected in all patients. Nine patients were homozygous for the c.402dupC (p.M135Hfs*28) mutation strongly suggesting a founder effect. On the other hand, 1 patient had a novel mutation, c.817_820delGACT (p.D273Sfs*37). CONCLUSION: This is the largest series of patients with HPMRS from same ethnic group. Our results reinforce the distinct clinical and facial features of PGAP3-related HPMRS which are the clue for targeted genetic testing. Moreover, we present additional unreported clinical and neuro-imaging findings and a novel mutation thus expanding the phenotypic and mutational spectrum of this rare disorder.
BACKGROUND:Hyperphosphatasia with mental retardation syndrome (HPMRS) is caused by recessive mutations in genes involved in the glycosylphosphatidylinsitol pathway, including PGAP3. MATERIALS AND METHODS: We describe 10 patients from 8 Egyptian families presenting with developmental delay, severe intellectual disability, distinct facial dysmorphism and increased alkaline phosphatase. Sanger sequencing of PGAP3 was performed. RESULTS: Eight patients had cleft palate, 4 had postnatal microcephaly and 5 had seizures. Neuro-imaging findings showed thin corpus callosum in 9 patients, mild ventriculomegaly in 3 patients and variable degrees of cerebellar vermis hypoplasia in 4 patients, a finding not previously reported in patients with HPMRS. Additional manifestations included double row teeth, hypogenitalism and congenital heart disease. Biallelic loss of function mutations in the PGAP3 gene were detected in all patients. Nine patients were homozygous for the c.402dupC (p.M135Hfs*28) mutation strongly suggesting a founder effect. On the other hand, 1 patient had a novel mutation, c.817_820delGACT (p.D273Sfs*37). CONCLUSION: This is the largest series of patients with HPMRS from same ethnic group. Our results reinforce the distinct clinical and facial features of PGAP3-related HPMRS which are the clue for targeted genetic testing. Moreover, we present additional unreported clinical and neuro-imaging findings and a novel mutation thus expanding the phenotypic and mutational spectrum of this rare disorder.
Authors: Kurt Reynolds; Shuwen Zhang; Bo Sun; Michael A Garland; Yu Ji; Chengji J Zhou Journal: Birth Defects Res Date: 2020-07-15 Impact factor: 2.344
Authors: B Pascual; S T de Bot; M R Daniels; M C França; C Toro; M Riverol; P Hedera; M T Bassi; N Bresolin; B P van de Warrenburg; B Kremer; J Nicolai; P Charles; J Xu; S Singh; N J Patronas; S H Fung; M D Gregory; J C Masdeu Journal: AJNR Am J Neuroradiol Date: 2019-01-03 Impact factor: 3.825
Authors: Alexej Knaus; Jean Tori Pantel; Manuela Pendziwiat; Nurulhuda Hajjir; Max Zhao; Tzung-Chien Hsieh; Max Schubach; Yaron Gurovich; Nicole Fleischer; Marten Jäger; Sebastian Köhler; Hiltrud Muhle; Christian Korff; Rikke S Møller; Allan Bayat; Patrick Calvas; Nicolas Chassaing; Hannah Warren; Steven Skinner; Raymond Louie; Christina Evers; Marc Bohn; Hans-Jürgen Christen; Myrthe van den Born; Ewa Obersztyn; Agnieszka Charzewska; Milda Endziniene; Fanny Kortüm; Natasha Brown; Peter N Robinson; Helenius J Schelhaas; Yvonne Weber; Ingo Helbig; Stefan Mundlos; Denise Horn; Peter M Krawitz Journal: Genome Med Date: 2018-01-09 Impact factor: 11.117